The Urinalysis Market in North America is expected to grow from US$ 1,432.01 million in 2021 to US$ 2,129.13 million by 2028; it is estimated to grow at a CAGR of 5.8% from 2021 to 2028. The urinalysis market is characterized by the presence of various small and big companies. The market players are adopting the strategies such as new product launches, regional expansions, and technological advancements to expand their market share. Rising demand for rapid tests, point-of-care (PoC) testing, and portable instruments are encouraging new product launches in the urinalysis market. The PoC testing enables rapid results in non-laboratory settings, along with boosting productivity. These tests are cost-effective and encompass the diagnoses of a wide range of diseases. Moreover, the growing demand for PoC diagnostics products is further driving product innovations in the urinalysis market. Market players are readily investing in R&D to develop advanced technologies.
North America Urinalysis Market Segmentation
North America Urinalysis Market –
By Product
- Consumables
- Instruments
North America Urinalysis Market – By
Test Type
- Pregnancy and Fertility Tests
- Biochemical Urinalysis
- Sediment Urinalysis
North America Urinalysis Market – By Application
- Disease Screening
- Pregnancy and Fertility
North America Urinalysis Market – By End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Home Care Settings
- Research Laboratories and Institutes
North America Urinalysis Market – By Country
- US
- Canada
- Mexico
North America Urinalysis Market – Company Profiles
- Abbott
- ACON Laboratories, Inc.
- ARKRAY, Inc.
- Beckman Coulter, Inc.
- Bio-Rad Laboratories Inc.
- Cardinal Health Inc
- F. Hoffmann-La Roche Ltd.
- Quidel Corporation
- Siemens Healthineers AG
- Sysmex Corporation
North America Urinalysis Market Overview
The North America urinalysis market spans the U.S., Canada, and Mexico, with the U.S. dominating due to its high prevalence of chronic diseases, robust R&D infrastructure, presence of major industry players, and rising healthcare expenditure. Increased awareness initiatives further drive demand for urinalysis tools, essential for diagnosing conditions like diabetes, kidney disorders, and UTIs.
COVID-19 Impact and Recovery
The pandemic initially disrupted the market, as lockdowns delayed routine health screenings, reducing demand for urinalysis products. However, emerging data linking COVID-19 to acute kidney injury (AKI) and chronic kidney disease shifted priorities. The National Kidney Foundation highlights that recovered COVID-19 patients with AKI or abnormal urinalysis results require ongoing monitoring, fueling long-term demand. Regulatory agility, such as expedited approvals for diagnostics, and strategic corporate partnerships (e.g., Sysmex America and Siemens Healthineers’ collaboration to expand CLINITEK Novus distribution) helped mitigate short-term challenges. As vaccination rates rise and healthcare systems stabilize, urinalysis demand is projected to rebound, driven by post-pandemic renal health surveillance.
Strategic Insights for Market Success
Competitive Landscape & Opportunities
-
Data-Driven Decision-Making: Leverage analytics to identify trends, regional variations, and unmet needs (e.g., point-of-care testing in underserved areas).
-
Differentiation Strategies: Develop niche offerings, such as AI-integrated urinalysis platforms or eco-friendly consumables, to stand out in a crowded market.
Future-Forward Planning
-
Anticipate Regulatory Shifts: Stay agile as authorities balance rapid diagnostics approvals with post-pandemic quality controls.
-
Invest in Innovation: Prioritize R&D for advanced automation, portable devices, and multi-parameter test strips to address rising chronic disease burdens.
Stakeholder Actions
-
Healthcare Providers: Expand screening programs for high-risk populations, including COVID-19 survivors.
-
Manufacturers: Forge partnerships to enhance distribution networks and integrate urinalysis into broader diagnostic ecosystems.
-
Investors: Target startups focusing on telehealth-compatible or home-testing solutions poised for growth.
Conclusion
Post-COVID recovery and heightened focus on renal health present significant growth opportunities. Stakeholders who embrace innovation, strategic collaborations, and data-driven insights will be best positioned to capitalize on the evolving urinalysis landscape in North America.
Other Reports:
North America Multiple Sclerosis Therapeutics Market: https://www.quora.com/profile/Business-Market-Insights-1/North-America-Multiple-Sclerosis-Therapeutics-Market-2027-Size-Share-Industry-Trends-Business-Revenue-Forecast-and-S
North America Artificial Intelligence in Market: https://penzu.com/p/6a525833f613cd65
North America Long Read Sequencing Market: https://postyourarticle.com/north-america-long-read-sequencing-market-analysis-trends-share-development-policies-and-future-growth-2028/
North America Stevia Market: https://sites.google.com/view/north-america-long-read-sequen/home
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio:
Suryakant Gadekar
Senior Market Research Expert at Business Market Insights
